Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alkermes Plc (NQ: ALKS )

27.83 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alkermes Plc

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Alkermes Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
Via Benzinga
NASDAQ:ALKS: good value for what you're paying.
For those who appreciate value investing, ALKERMES PLC (NASDAQ:ALKS) is a compelling option with its solid fundamentals. 
Via Chartmill
Despite its impressive fundamentals, NASDAQ:ALKS remains undervalued.
For those who appreciate value investing, ALKERMES PLC (NASDAQ:ALKS) is a compelling option with its solid fundamentals. 
Via Chartmill
NASDAQ:ALKS stands out as a stock that provides good value for the fundamentals it showcases.
Investors should take notice ofALKERMES PLC (NASDAQ:ALKS)—it offers a great deal for the fundamentals it presents. 
Via Chartmill
ALKS Stock Earnings: Alkermes Beats EPS, Beats Revenue for Q2 2024
ALKS stock results show that Alkermes beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
AT&T, Group 1 Automotive, Mattel, Seagate And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
6 Analysts Assess Alkermes: What You Need To Know
Via Benzinga
The Analyst Landscape: 7 Takes On Alkermes
Via Benzinga
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
"Rule Breaker Investing" Stock Pick Review: The Big One
Looking back at 30 five-stock samplers picked from 2015 to 2021. 
Via The Motley Fool
6 Analysts Assess Alkermes: What You Need To Know
Via Benzinga
7 Analysts Assess Alkermes: What You Need To Know
Via Benzinga
NASDAQ:ALKS is an undervalued gem with solid fundamentals.
Investors should take notice ofALKERMES PLC (NASDAQ:ALKS)—it offers a great deal for the fundamentals it presents. 
Via Chartmill
When you look at NASDAQ:ALKS, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Don't overlook ALKERMES PLC (NASDAQ:ALKS)—it's a hidden gem with strong fundamentals and an attractive price tag. 
Via Chartmill
In a market where value is scarce, NASDAQ:ALKS offers a refreshing opportunity with its solid fundamentals.
Don't overlook ALKERMES PLC (NASDAQ:ALKS)—it's a hidden gem with strong fundamentals and an attractive price tag. 
Via Chartmill
3 Biotech Stocks That Could Be Millionaire-Makers: May Edition
Investors should take a close look at these biotech stocks as they position themselves to provide high returns. 
Via InvestorPlace
Investors should take notice of NASDAQ:ALKS—it offers a great deal for the fundamentals it presents.
ALKERMES PLC (NASDAQ:ALKS) is probably undervalued for the fundamentals it is displaying. 
Via Chartmill
Exploring growth characteristics of ALKERMES PLC (NASDAQ:ALKS).
Should you consider ALKERMES PLC (NASDAQ:ALKS) for growth investing? 
Via Chartmill
Exploring growth characteristics of ALKERMES PLC (NASDAQ:ALKS).
ALKERMES PLC (NASDAQ:ALKS) may be suited for growth investing, we'll explore why in this article. 
Via Chartmill
Breaking Down Alkermes: 5 Analysts Share Their Views
Via Benzinga
Is NASDAQ:ALKS suited for growth investing?
Is ALKERMES PLC (NASDAQ:ALKS) suited for growth investing? 
Via Chartmill
ALKS Stock Earnings: Alkermes Misses EPS, Misses Revenue for Q1 2024
ALKS stock results show that Alkermes missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Investors should take notice of NASDAQ:ALKS—it offers a great deal for the fundamentals it presents.
Don't overlook ALKERMES PLC (NASDAQ:ALKS)—it's a hidden gem with strong fundamentals and an attractive price tag. 
Via Chartmill
Alkermes' Sleeping Disorder Studies' Data Look Excellent, Analyst Says
ALKS 2680 reports positive results in narcolepsy & idiopathic hypersomnia study. Statistically significant improvements in sleep latency were observed across all doses tested. Phase 2 study for NT2... 
Via Benzinga
When you look at NASDAQ:ALKS, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
When you look at ALKERMES PLC (NASDAQ:ALKS), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
The Analyst Verdict: Alkermes In The Eyes Of 4 Experts
Via Benzinga
A Look Into Healthcare Sector Value Stocks
Via Benzinga
Exploring NASDAQ:ALKS's growth characteristics.
Why the growth investor may take a look at NASDAQ:ALKS. 
Via Chartmill
Amicus Therapeutics Stock Sees RS Rating Improve To 74
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday. 
Via Investor's Business Daily
NASDAQ:ALKS stands out as a stock that provides good value for the fundamentals it showcases.
ALKERMES PLC (NASDAQ:ALKS) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.